Highlights:
 Abnormal cerebral glutamate release has been implicated in the pathogenesis of stroke and epilepsy  Glutamate levels in acute stroke may be a biomarker for the development of post-stroke epilepsy  7T MRI technology enables non-invasive quantification of cerebral glutamate levels Abstract Stroke is one of the most important causes of acquired epilepsy in the adult population. While factors such as cortical involvement and haemorrhage have been associated with increased seizure risk, the mechanisms underlying the development of epilepsy after stroke remain unclear. One hypothesised mechanism is an excitotoxic effect of abnormal glutamate release following a stroke. Cerebral extracellular glutamate levels are known to rise in the setting of acute stroke, and numerous studies have implicated glutamate in the pathogenesis of seizures and epilepsy, both through direct measurement of glutamate from the epileptic brain and by analysis of receptors and transporters central to glutamate homeostasis. While experimental evidence suggests the cellular injury induced by glutamate exposure may lead to development of an epileptic phenotype, there is little direct data linking the rise in glutamate during stroke with the later development of epilepsy.
Clinical research in this field has been hampered by the lack of non-invasive methods to measure cerebral glutamate. However, with the increasing availability of 7T MRI technology, Magnetic Resonance Spectroscopy is able to better resolve glutamate from other chemical species at this field strength, and Glutamate Chemical Exchange Saturation Transfer (GluCEST) imaging has been applied to localise epileptic foci in non-lesional focal epilepsy.
This review outlines the evidence implicating a pivotal role for cerebral glutamate in the development of post-stroke epilepsy, and exploring the role of MRI in studying glutamate as a biomarker and therefore its suitability as a molecular target for anti-epileptogenic therapies. We hypothesise that the rise in glutamate levels in the setting of acute stroke is a clinically relevant biomarker for the development of post-stroke epilepsy. systematic review and pooled analysis of 102008 patients 5 showed an overall incidence of post-stroke seizures of 7%, with those with haemorrhagic stroke or cortical involvement at higher risk. There is evidence that stroke associated with venous sinus thrombosis also confers a higher risk of seizures 6 .
Revised definition of post-stroke epilepsy
According to the International League Against Epilepsy, acute symptomatic seizures are defined as those seizures occurring in close temporal association with a brain insult. This is reflected in the differentiation between "early" and "late" post-stroke seizures, with the latter defined as occurring more than 7 days after the stroke 7 . While epilepsy has historically been defined as two or more unprovoked seizures, the revised ILAE definition of epilepsy from 2014 included individuals with one unprovoked seizure and a probability of further seizures similar to the general recurrence risk after two unprovoked seizures, occurring over the next 10 years 8 . Hence according to the new definition an individual experiencing one post-stroke seizure at least one month after stroke (or two seizures at least 7 days after stroke) can be diagnosed with epilepsy. This is consistent with previous observational studies that show most patients with one late post-stroke seizure will go on to develop recurrent seizures 9 .
Risk factors for post-stroke epilepsy Galovic and colleagues recently proposed a multivariable prediction model for the development of late seizures after ischaemic stroke, drawing on five identified predictive factors of stroke severity, large artery atherosclerotic aetiology, early seizures, cortical involvement and middle cerebral artery territory involvement 10 . Based on this algorithm, those at highest risk were determined to have a post-stroke epilepsy risk of 83% within five years.
Our research group has reported several risk factors for the development of post-ischaemic stroke seizures, including cortical involvement 11 , a low Alberta Stroke Program Early CT Score (ASPECTS) score 12 and haemorrhagic transformation 13 . We have also demonstrated that implementation of a code stroke system reduces the risk of post-stroke epilepsy 14 .
Treatment and prevention of post-stroke epilepsy While anti-epileptic drugs form the first line for management of post-stroke epilepsy the optimal timing and choice of drug have not been established.
There have not been any randomised controlled trials comparing an antiepileptic drug with placebo for the secondary prevention of post-stroke seizures (i.e. after the occurrence of one or more seizures). A recent Cochrane review commented on three randomised trials comparing different secondary prevention therapies 15 , only one of which examined a cohort in which stroke was the only aetiology for the seizures 16 . Across these studies lamotrigine was shown to be both efficacious and to have a superior tolerability profile to the other agents. Levetiracetam may also be a safe and effective option in elderly patients 17 . Post-stroke seizures generally respond well to anti-epileptic drug treatment: Gilad and coworkers observed seizure freedom in 37/64 patients over a 12 month follow-up period 16 .
Two studies have examined anti-epileptic drugs for the primary prevention of seizures after stroke (i.e. anti-epileptogenic therapy). Van Tujil et al 18 studied
whether the short-term (14 week) administration of levetiracetam would prevent the development of epilepsy after stroke. This study was prematurely terminated due to slow recruitment rates. A randomised controlled trial with a placebo group has examined the role of short-term antiepileptic therapy to prevent late seizures after haemorrhagic stroke 19 ; the authors found that treatment with sodium valproate for one month did not affect seizure risk. Our group has reported that patients developing haemorrhagic transformation after receiving reperfusion therapy for acute ischaemic stroke are at higher risk of epilepsy and may benefit from longer follow-up 20 .
Glutamate
For an effective anti-epileptogenic therapy to be developed, consideration needs to be given to the identification of biomarkers for patients at most risk of developing post-stroke seizures. While various studies have looked at the peri-stroke exposome and association with seizures, including relevant comorbidities, metabolic disturbance and concomitant pharmacotherapy, no other biomarkers have been identified 21 .
Cerebral glutamate may be a biomarker of post-stroke seizures. Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system and plays a key role in normal brain function. Most brain glutamate is present intracellularly however as glutamate receptors are located on the cell surface its extracellular concentration determines the extent of stimulation 22 .
Glutamate-mediated excitotoxicity refers to the process by which excessive stimulation of glutamate receptors induces neuronal cell death, a process implicated in several neurological disorders including stroke, epilepsy, brain trauma and chronic neurodegenerative disorders 23 . Overstimulation of glutamate receptors induces cell death by multiple effects including impairment of intracellular calcium homeostasis, activation of proteases and kinases, increased nitric oxide and expression of pro-death transcription factors 23 .
Activation of glutamate receptors has been shown to contribute to ischaemic cell death in stroke by impairing ion homeostasis with a resultant increase in intracellular calcium concentration 24 . Tissue oedema arises through influx of sodium and chloride ions and subsequently water, impairing perfusion of regions surrounding the ischaemic core.
It is well documented however that changes in the strength of excitatory synapses play an important role in synaptic plasticity 25 and it is postulated that glutamate receptor signalling may therefore play a different role in the recovery from stroke to during the phase of acute ischaemia 26 . Among the evidence supportive of this theory is the observation that motor recovery is enhanced by increased α-amino-3-hydroxy-5-methyld-4-isoxazolepropionic acid (AMPA) receptor signalling 27 . Chronic treatment with the N-methyl Daspartate (NMDA) receptor antagonist memantine, however, improved recovery from stroke in an animal model 28 .
Glutamate and stroke
In animal models, acute elevation of glutamate levels have been observed after stroke 29 with the highest elevations seen in those with the largest infarctions. Other studies however have demonstrated a decrease in glutamate levels, postulated due to a combination of decreased glutamate synthesis and loss of brain glutamate via cerebrospinal fluid and the systemic circulation 30 . In human studies, elevated intra-cerebral glutamate levels, as measured from cerebrospinal fluid, have been demonstrated in acute stroke 31 with glutamate levels in both CSF and plasma correlated with infarction lesion and severity of neurological deficit (see figure) . Glutamate elevation has also been implicated in the pathogenesis of haemorrhagic stroke, however this may involve a different mechanism through Src kinase activation and phosphorylation of glutamate receptors 32 . histologically similar brain tumours without epilepsy 36, 37 .
There are other lines of evidence implicating glutamate in the pathogenesis of epilepsy and epileptogenesis. Changes in excitatory and inhibitory glutamate transporters, for example, have been observed in epileptogenic brain regions 38 , and experimentally altering the function of glutamate receptor proteins can induce epilepsy syndromes 39 .
Modulation of glutamate levels as a therapeutic target
The experience with glutamate receptor antagonists in stroke has however been a disappointing one. For example, despite observed neuroprotective properties in animal studies, clinical trials of the NMDA receptor antagonist selfotel were stopped prematurely due to a trend toward increased mortality in the treatment group 40 with similar failures observed in the setting of traumatic brain injury 41 . A trial of the AMPA receptor antagonist ZK200775 was also stopped due to transient neurological deterioration in the treatment group 42 .
While some have cited pharmacokinetic factors and poor trial design as possible explanations for the failure, it has also been postulated that synaptic activity mediated by NMDA receptors may promote survival of neurons in this setting 43 .
Several studies have looked at the role of modulators of the glutamate pathway in both treating epilepsy and preventing epileptogenesis. A wellknown example is the non-competitive, selective AMPA receptor antagonist perampanel, approved as adjunctive treatment for refractory focal and generalised seizures based on demonstrated efficacy in several multi-centre randomised trials of patients with uncontrolled focal and generalised seizures 44 . While it is not known if perampanel has anti-epileptogenic properties in humans, in animal studies it has been shown to modulate the development of epilepsy induced by kindling techniques 45 . It has also been shown to improve cognitive outcome after middle cerebral artery occlusion in rats although the association with development of seizures was not specifically studied 46 .
Numerous other studies have demonstrated attenuation of epileptogenesis through modulation of both ionotropic and metabotropic glutamate receptors.
Administration of pre-synaptic metabotropic glutamate agonists has been shown to block the development of epileptogenesis, correlated with a decrease in glutamate release from cortical synaptosomes 47 as has antagonism of excitatory metabotropic receptors prior to administration of pilocarpine 48 . NMDA receptor antagonists have been shown to suppress the development of epilepsy from amygdala kindling 49 Interestingly this pattern was associated with better clinical outcomes after reperfusion.
MRS has also been used extensively in the study of epilepsy. A systematic review of MRS studies in juvenile myoclonic epilepsy identified metabolic changes across a range of brain regions including the thalamus, frontal lobe insula and striatum 58 . Regional increases in the glutamate-glutamine complex (Glx) may be the result of hyperexcitability 59 .
Several studies of focal epilepsy have showed reduced NAA ipsilateral to seizure focus, [60] [61] [62] including in non-lesional cases 63 and the glutamine plus glutamate (Glx) to NAA and Choline ratios can correctly identify the epileptogenic zone in patients with temporal lobe epilepsy 64 . In an MRS study of focal cortical dysplasia 65 , patients had elevated levels of glutamine/glutamate and reduced levels of NAA compared with controls.
Other studies have shown that higher concordance between MRS abnormalities and region of surgical resection is associated with better surgical outcomes 66 .
For measurement of glutamate, PRESS and MEGA-PRESS techniques have shown excellent in vitro agreement between actual and measured glutamate concentrations, as well as good repeatability at 3T 67 . Clinically, elevated glutamate concentrations have been associated with seizures in a population of glioma patients with epilepsy 68 and another study showed a correlation between glutamine/glutamate (Glx) levels on MRS and frequency and duration of seizures in neonatal hypoxic-ischaemic encephalopathy 69 .
Glutamate is difficult to separate from glutamine at 1.5T; at higher field strengths, improved separation is possible although factors such as increased One problem is the extent of release of glutamate in the ischaemic core compared with the ischaemic penumbra and its association with epileptogenesis: experimental data suggests it is the ischaemic penumbra rather than the core that is responsible for epileptogenesis 54 , consistent with the hypothesis that dead neurons do not generate epileptiform discharges, although in animal models of ischaemia the extent of elevation of extracellular glutamate levels is significantly higher in the core 76 . Furthermore the toxic effect of glutamate may be offset by the neuroprotective effect of extracellular acidity in the setting of acute stroke 77 ; it is possible though that tissue acidosis may protect against infarct growth but not against the cellular excitability and The advent of 7T MRI technology represents a new opportunity to study intracerebral glutamate levels following stroke in an in-vivo setting, both through Magnetic Resonance Spectroscopy and utilising the GluCEST technique. Accordingly we will be able to better understand the temporal changes in glutamate levels after a stroke and identify the optimal time point for glutamate receptor antagonism as an anti-epileptogenic strategy. One caveat is that GluCEST contrast is pH dependent and needs to be interpreted in the setting of tissue acidosis, and non-invasive imaging techniques cannot necessarily differentiate between extracellular and intracellular glutamate content. The non-selective, competitive AMPA receptor antagonist perampanel represents a possible anti-epileptogenic agent; it has shown neuroprotective effects in animal models and has an established role in the treatment of epilepsy.
While the search for anti-epileptogenic therapies has thus far been a challenging one, developing a better understanding of the pathogenesis of post-stroke epileptogenesis and implementing potential neuro-protective strategies represents an opportunity to improve the quality of lives of those suffering from a common and serious long term sequela of stroke.
